NEUREN PHARMACEUTICALS LTD

Neuren Pharmaceuticals boosts neurological & metabolic disorder research, driving biopharma innovation and investor confidence with a strong $2.9B market cap.

Neuren Pharmaceuticals Ltd. has reported a significant recovery in its stock price and market capitalization, driven by investor confidence in its growth potential and ongoing research efforts in neurological and metabolic disorders.